SCHEMBL3263798

SCHEMBL3263798

C=C(SCc1ccccc1)C(=C)[S+]([O-])Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 8/20 0.42
NOS1 P29475 2/20 0.42
NOS3 P29474 1/20 0.42
NOS2 P35228 1/20 0.42
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
TDP1 Q9NUW8 2/20 0.35
GAA P10253 2/20 0.35
TAAR1 Q96RJ0 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
SLC11A2 P49281 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3262714 0.83 IDO1 (0.44) IDO1NOS1NOS3NOS2CA12
SCHEMBL10709613 0.71 IDO1 (0.50) IDO1NOS1NOS3NOS2CA12
SCHEMBL12651739 0.69 IDO1 (0.58) IDO1NOS1NOS3NOS2CA12
SCHEMBL7521246 0.68 IDO1 (0.37) IDO1NOS1NOS3NOS2CA12
SCHEMBL12349707 0.66 IDO1 (0.54) IDO1NOS1NOS3NOS2CA12
SCHEMBL10256504 0.66 CES1 (0.50) CYP1A2
SCHEMBL19406968 0.66 IDO1 (0.53) IDO1NOS1NOS3NOS2CA12
SCHEMBL12971436 0.65 IDO1 (0.52) IDO1NOS1NOS3NOS2CA12
SCHEMBL10391146 0.65 CTSL (0.39) IDO1NOS1NOS3NOS2CA12
SCHEMBL8650688 0.64 IDO1 (0.44) IDO1NOS1NOS3NOS2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7744889-B2 Alpha, beta-unsaturated sulfoxides for treating proliferative disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2010-06-29 US disclosed
US-20060280746-A1 (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents ONCONOVA THERAPEUTICS INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060280746-A1 (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents SULT1E1, GSTO1, CCNA1 IDO1 1158/4885NOS1 568/4885NOS3 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.